Egalognastat

Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex) . Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) [1].

Product Specifications

CAS Number

[1884154-02-2]

Product Name Alternative

ASN90

UNSPSC

12352005

Target

OGA; Tau Protein

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/asn90.html

Purity

99.63

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

CC(NC1=NN=C(N2CCN(CC2)[C@H](C3=CC=C(OCO4)C4=C3)C)S1)=O

Molecular Formula

C17H21N5O3S

Molecular Weight

375.45

References & Citations

[1]Permanne B, et al. O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies. ACS Chem Neurosci. 2022 Apr 20;13 (8) :1296-1314.